Wall Street analysts expect that Vascular Biogenics Ltd. (NASDAQ:VBLT) will report earnings per share of ($0.20) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vascular Biogenics’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.22). Vascular Biogenics posted earnings of ($0.18) per share in the same quarter last year, which suggests a negative year over year growth rate of 11.1%. The business is expected to issue its next earnings results on Monday, March 26th.

According to Zacks, analysts expect that Vascular Biogenics will report full-year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.70). For the next financial year, analysts forecast that the business will post earnings of ($0.93) per share, with EPS estimates ranging from ($1.02) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Vascular Biogenics.

A number of brokerages have commented on VBLT. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, November 24th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Vascular Biogenics in a research note on Tuesday, November 21st. Chardan Capital boosted their price target on shares of Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Finally, ValuEngine lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $15.67.

Shares of Vascular Biogenics (NASDAQ VBLT) opened at $6.95 on Wednesday. Vascular Biogenics has a one year low of $3.90 and a one year high of $9.05.

An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.59% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/13/vascular-biogenics-ltd-vblt-expected-to-post-earnings-of-0-20-per-share.html.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.